[Federal Register Volume 73, Number 74 (Wednesday, April 16, 2008)]
[Notices]
[Page 20614]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-8204]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Intent To Grant an Exclusive License of a U.S. Government-Owned 
Patent

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(I)(i), 
announcement is made of the intent to grant an exclusive, royalty-
bearing, revocable license to U.S. Patent 6,825,323, filed January 10, 
2001, entitled ``Compositions for treatment of hemorrhaging with 
activated factor VIIa in combination with fibrinogen and methods of 
using the same'' and foreign rights (PCT/US01/000725) to ProFibrix 
B.V., with its principal place of business at Zernikedreef 9, 2333 CK 
Leiden, The Netherlands.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-ZA-J, 504 Scott Street, Fort 
Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele, 
Office of Research & Technology Assessment, (301) 619-6664. For patent 
issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808, both at 
telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Anyone wishing to object to the grant of 
this license can file written objections along with supporting 
evidence, if any, within 15 days from the date of this publication. 
Written objections are to be filed with the Command Judge Advocate (see 
ADDRESSES).

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E8-8204 Filed 4-15-08; 8:45 am]
BILLING CODE 3710-08-P